{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:35:32Z","timestamp":1793237732737,"version":"4.5.0"},"reference-count":107,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Before the advent of effective iron chelation, death from iron-induced cardiomyopathy and endocrine failure occurred in the second decade in patients with thalassemia major, and this experience has driven expectation of poor outcomes and caused anxiety in all disorders associated with iron loading to this day. To be clear, severe iron overload still causes significant morbidity and mortality in many parts of the world, but current understanding of iron metabolism, noninvasive monitoring of organ-specific iron loading in humans, and effective iron chelators have dramatically reduced morbidity of iron overload. Furthermore, clinical experience in hemoglobinopathies supports iron biology learned from animal studies and identifies common concepts in the biology of iron toxicity that inform the management of iron toxicity in several human disorders. The resultant significant increase in survival uncovers new complications due to much longer exposure to anemia and to iron, which must be considered in long-term therapeutic strategies. This review will discuss the management of iron toxicity in patients with hemoglobinopathies and transfusion-dependent anemias and how iron biology informs the clinical approach to treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023022502","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T16:18:37Z","timestamp":1726676317000},"page":"359-371","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["Management of iron overload: lessons from transfusion-dependent hemoglobinopathies"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9878-6029","authenticated-orcid":false,"given":"Thomas D.","family":"Coates","sequence":"first","affiliation":[{"name":"Cancer and Blood Disease Institute, Children\u2019s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2025013017461258300_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1749-6632.1969.tb27814.x","article-title":"Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen","volume":"165","author":"Piomelli","year":"1969","journal-title":"Ann N Y Acad Sci"},{"issue":"0","key":"2025013017461258300_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1749-6632.1974.tb20584.x","article-title":"Hypertransfusion regimen in patients with Cooley's anemia","volume":"232","author":"Piomelli","year":"1974","journal-title":"Ann N Y Acad Sci"},{"issue":"6322","key":"2025013017461258300_bib3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/bmj.284.6322.1081","article-title":"Survival and desferrioxamine in thalassaemia major","volume":"284","author":"Modell","year":"1982","journal-title":"Br Med J"},{"key":"2025013017461258300_bib4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/01.CIR.30.5.698","article-title":"Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis","volume":"30","author":"Engle","year":"1964","journal-title":"Circulation"},{"issue":"1","key":"2025013017461258300_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","article-title":"Results of long-term iron-chelating therapy","volume":"95","author":"Gabutti","year":"1996","journal-title":"Acta Haematol"},{"issue":"9220","key":"2025013017461258300_bib6","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","article-title":"Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register","volume":"355","author":"Modell","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"2025013017461258300_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.26798","article-title":"Overall and complication-free survival in a large cohort of patients with beta-thalassemia major followed over 50 years","volume":"98","author":"Forni","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"2025013017461258300_bib8","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2005-07-2933","article-title":"Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major","volume":"107","author":"Borgna-Pignatti","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2025013017461258300_bib9","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1182\/blood.2023022460","article-title":"Pretransfusion hemoglobin level and mortality in adults with transfusion-dependent beta-thalassemia","volume":"143","author":"Musallam","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2025013017461258300_bib10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood.2023023294","article-title":"Higher hemoglobin is better in thalassemia","volume":"143","author":"Coates","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025013017461258300_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1532-429X-10-42","article-title":"Improved survival of thalassaemia major in the UK and relation to T2\u2217 cardiovascular magnetic resonance","volume":"10","author":"Modell","year":"2008","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"issue":"1","key":"2025013017461258300_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jmri.22621","article-title":"Impact of magnetic resonance imaging on cardiac mortality in thalassemia major","volume":"34","author":"Chouliaras","year":"2011","journal-title":"J\u00a0Magn Reson Imag"},{"issue":"3","key":"2025013017461258300_bib13","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.12517","article-title":"Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major","volume":"163","author":"Origa","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"2025013017461258300_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1600-0609.2011.01582.x","article-title":"Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population","volume":"86","author":"Ladis","year":"2011","journal-title":"Eur J Haematol"},{"issue":"3","key":"2025013017461258300_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MOH.0b013e3280d2b76b","article-title":"Magnetic resonance imaging measurement of iron overload","volume":"14","author":"Wood","year":"2007","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"2025013017461258300_bib16","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2004-10-3982","article-title":"MRI R2 and R2\u2217 mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients","volume":"106","author":"Wood","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2025013017461258300_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1182\/blood.V88.2.705.bloodjournal882705","article-title":"Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy","volume":"88","author":"Porter","year":"1996","journal-title":"Blood"},{"issue":"3","key":"2025013017461258300_bib18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05202.x","article-title":"Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2\u2217 cardiovascular magnetic resonance","volume":"127","author":"Anderson","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"2025013017461258300_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1532-429X-13-45","article-title":"On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure","volume":"13","author":"Pennell","year":"2011","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"2025013017461258300_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fphar.2014.00045","article-title":"Labile iron in cells and body fluids: physiology, pathology, and pharmacology","volume":"5","author":"Cabantchik","year":"2014","journal-title":"Front Pharmacol"},{"issue":"Pt A","key":"2025013017461258300_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.freeradbiomed.2015.07.019","article-title":"Iron and oxidative stress in cardiomyopathy in thalassemia","volume":"88","author":"Berdoukas","year":"2015","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2025013017461258300_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ajh.20402","article-title":"Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia","volume":"80","author":"Vichinsky","year":"2005","journal-title":"Am J Hematol"},{"issue":"2","key":"2025013017461258300_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.hoc.2022.12.006","article-title":"Pathogenic mechanisms in thalassemia II: iron overload","volume":"37","author":"Ganz","year":"2023","journal-title":"Hematol Oncol Clin N Am"},{"issue":"1","key":"2025013017461258300_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/nyas.13060","article-title":"Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?","volume":"1368","author":"Coates","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"2025013017461258300_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.freeradbiomed.2014.03.039","article-title":"Physiology and pathophysiology of iron in hemoglobin-associated diseases","volume":"72","author":"Coates","year":"2014","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"2025013017461258300_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ajh.24674","article-title":"Transplantation in thalassemia: revisiting the Pesaro risk factors 25 years later","volume":"92","author":"Angelucci","year":"2017","journal-title":"Am J Hematol"},{"issue":"3","key":"2025013017461258300_bib27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2016.12.034","article-title":"A\u00a0red carpet for iron metabolism","volume":"168","author":"Muckenthaler","year":"2017","journal-title":"Cell"},{"issue":"3","key":"2025013017461258300_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.26819","article-title":"The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron-carbohydrate administration","volume":"98","author":"Garbowski","year":"2023","journal-title":"Am J Hematol"},{"key":"2025013017461258300_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.freeradbiomed.2018.10.413","article-title":"Non-transferrin-bound iron transporters","volume":"133","author":"Knutson","year":"2019","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2025013017461258300_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/asheducation-2017.1.265","article-title":"Iron overload in thalassemia: different organs at different rates","volume":"2017","author":"Taher","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7498","key":"2025013017461258300_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13148","article-title":"Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy","volume":"509","author":"Mancias","year":"2014","journal-title":"Nature"},{"issue":"1","key":"2025013017461258300_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2018-07-815928","article-title":"Iron metabolism under conditions of ineffective erythropoiesis in beta-thalassemia","volume":"133","author":"Rivella","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2025013017461258300_bib33","first-page":"117","article-title":"[The reticuloendothelial system: an overview of function, pathology and recent methods of measurement]","volume":"32","author":"Baas","year":"1994","journal-title":"Z\u00a0Gastroenterol"},{"issue":"5","key":"2025013017461258300_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200008033430503","article-title":"Hepatic iron concentration and total body iron stores in thalassemia major","volume":"343","author":"Angelucci","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025013017461258300_bib35","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000355192","article-title":"Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation","volume":"131","author":"Naoum","year":"2014","journal-title":"Acta Haematol"},{"issue":"3","key":"2025013017461258300_bib36","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1365-2141.2001.02820.x","article-title":"Non-transferrin-bound iron during allogeneic stem cell transplantation","volume":"113","author":"Sahlstedt","year":"2001","journal-title":"Br J Haematol"},{"issue":"10","key":"2025013017461258300_bib37","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3324\/haematol.2017.170605","article-title":"Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin","volume":"102","author":"Garbowski","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2025013017461258300_bib38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1600-0609.2009.01310.x","article-title":"Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation","volume":"83","author":"Sahlstedt","year":"2009","journal-title":"Eur J Haematol"},{"issue":"2","key":"2025013017461258300_bib39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2141.1997.4143221.x","article-title":"Non-transferrin-bound iron induced by myeloablative chemotherapy","volume":"99","author":"Bradley","year":"1997","journal-title":"Br J Haematol"},{"issue":"3","key":"2025013017461258300_bib40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood.2022019049","article-title":"Non\u2013transferrin-bound iron takes the driver\u2019s seat","volume":"141","author":"Knutson","year":"2023","journal-title":"Blood"},{"issue":"31","key":"2025013017461258300_bib41","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1074\/jbc.R117.786632","article-title":"Iron transport proteins: gateways of cellular and systemic iron homeostasis","volume":"292","author":"Knutson","year":"2017","journal-title":"J\u00a0Biol Chem"},{"issue":"7","key":"2025013017461258300_bib42","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3324\/haematol.2012.072314","article-title":"ZIP14 and DMT1 in the liver, pancreas, and heart are differentially regulated by iron deficiency and overload: implications for tissue iron uptake in iron-related disorders","volume":"98","author":"Nam","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"2025013017461258300_bib43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/ars.2020.8155","article-title":"The role of iron in benign and malignant hematopoiesis","volume":"35","author":"Sinha","year":"2021","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"2025013017461258300_bib44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.beha.2004.10.003","article-title":"LPI-labile plasma iron in iron overload","volume":"18","author":"Cabantchik","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"14","key":"2025013017461258300_bib45","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2009-09-243568","article-title":"Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease","volume":"115","author":"Inati","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2025013017461258300_bib46","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjh.13081","article-title":"Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients","volume":"167","author":"Porter","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"2025013017461258300_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1751-553X.2010.01224.x","article-title":"Nontransferrin-bound iron in transfused patients with sickle cell disease","volume":"33","author":"Inati","year":"2011","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"2025013017461258300_bib48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2141.2006.06277.x","article-title":"Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease","volume":"135","author":"Walter","year":"2006","journal-title":"Br J Haematol"},{"issue":"11","key":"2025013017461258300_bib49","doi-asserted-by":"crossref","first-page":"E283","DOI":"10.1002\/ajh.23543","article-title":"Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age","volume":"88","author":"Berdoukas","year":"2013","journal-title":"Am J Hematol"},{"issue":"5","key":"2025013017461258300_bib50","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14575","article-title":"How we manage iron overload in sickle cell patients","volume":"177","author":"Coates","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"2025013017461258300_bib51","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bjh.13791","article-title":"Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial","volume":"172","author":"Wood","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"2025013017461258300_bib52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2141.2010.08476.x","article-title":"Pancreatic iron loading in chronically transfused sickle cell disease is lower than in thalassaemia major","volume":"152","author":"Noetzli","year":"2011","journal-title":"Br J Haematol"},{"issue":"7","key":"2025013017461258300_bib53","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ajh.23721","article-title":"Cardiac iron overload in sickle-cell disease","volume":"89","author":"Meloni","year":"2014","journal-title":"Am J Hematol"},{"issue":"11","key":"2025013017461258300_bib54","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1182\/blood-2006-09-048868","article-title":"Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin","volume":"109","author":"Gardenghi","year":"2007","journal-title":"Blood"},{"issue":"16","key":"2025013017461258300_bib55","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood.2021011045","article-title":"Ineffective erythropoiesis and its treatment","volume":"139","author":"Cazzola","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025013017461258300_bib56","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood.2023020683","article-title":"How I treat non-transfusion-dependent beta-thalassemia","volume":"142","author":"Saliba","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025013017461258300_bib57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cncr.34509","article-title":"Incidence of cancer and related deaths in hemoglobinopathies: a follow-up of 4631 patients between 1970 and 2021","volume":"129","author":"Origa","year":"2023","journal-title":"Cancer"},{"key":"2025013017461258300_bib58","first-page":"blood.2024025462","article-title":"Significant pituitary siderosis is common in transfusion dependent sickle cell disease","author":"Vadivelan","year":"2024","journal-title":"Blood"},{"issue":"19","key":"2025013017461258300_bib59","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2009-06-225615","article-title":"Pancreatic iron loading predicts cardiac iron loading in thalassemia major","volume":"114","author":"Noetzli","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2025013017461258300_bib60","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2008-04-148767","article-title":"Longitudinal analysis of heart and liver iron in thalassemia major","volume":"112","author":"Noetzli","year":"2008","journal-title":"Blood"},{"issue":"20","key":"2025013017461258300_bib61","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2\u2217 magnetic resonance for prediction of cardiac complications in thalassemia major","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"2025013017461258300_bib62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ajh.22247","article-title":"Pituitary iron and volume predict hypogonadism in transfusional iron overload","volume":"87","author":"Noetzli","year":"2012","journal-title":"Am J Hematol"},{"issue":"2","key":"2025013017461258300_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.22223","article-title":"Pancreatic iron and glucose dysregulation in thalassemia major","volume":"87","author":"Noetzli","year":"2012","journal-title":"Am J Hematol"},{"issue":"9","key":"2025013017461258300_bib64","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2006-05-020867","article-title":"Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences","volume":"108","author":"Glickstein","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2025013017461258300_bib65","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood-2003-03-0807","article-title":"Labile plasma iron in iron overload: redox activity and susceptibility to chelation","volume":"102","author":"Esposito","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2025013017461258300_bib66","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2004-02-0630","article-title":"Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia\/HbE patients treated with an oral chelator","volume":"104","author":"Pootrakul","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2025013017461258300_bib67","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2004-01-0177","article-title":"Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance","volume":"105","author":"St Pierre","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2025013017461258300_bib68","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bjh.13119","article-title":"Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia","volume":"168","author":"Taher","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2025013017461258300_bib69","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1002\/ajh.24628","article-title":"Serum ferritin values between 300 and 800 ng\/mL in nontransfusion-dependent thalassemia: a probability curve to guide clinical decision making when MRI is unavailable","volume":"92","author":"Saliba","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"2025013017461258300_bib70","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ajh.23650","article-title":"Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload","volume":"89","author":"Puliyel","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"2025013017461258300_bib71","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1532-429X-15-24","article-title":"On myocardial siderosis and left ventricular dysfunction in hemochromatosis","volume":"15","author":"Carpenter","year":"2013","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"issue":"3","key":"2025013017461258300_bib72","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1002\/ajh.25009","article-title":"Lack of correlation between heart, liver and pancreas MRI-R2\u2217: results from long-term follow-up in a cohort of adult beta-thalassemia major patients","volume":"93","author":"Pinto","year":"2018","journal-title":"Am J Hematol"},{"key":"2025013017461258300_bib73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bcmd.2017.08.002","article-title":"Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: a multicenter study based on real-world data","volume":"66","author":"Krittayaphong","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"8","key":"2025013017461258300_bib74","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1097\/HS9.0000000000000732","article-title":"2021 Thalassaemia International Federation guidelines for the management of transfusion-dependent thalassemia","volume":"6","author":"Farmakis","year":"2022","journal-title":"Hemasphere"},{"issue":"2","key":"2025013017461258300_bib75","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000345734","article-title":"Cross-talk between available guidelines for the management of patients with beta-thalassemia major","volume":"130","author":"Musallam","year":"2013","journal-title":"Acta Haematol"},{"issue":"22","key":"2025013017461258300_bib76","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.3390\/ijms21228771","article-title":"Management of iron overload in beta-thalassemia patients: clinical practice update based on case series","volume":"21","author":"Pinto","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025013017461258300_bib77","doi-asserted-by":"crossref","first-page":"e221856","DOI":"10.1148\/radiol.221856","article-title":"Quantification of liver iron overload with MRI: review and guidelines from the ESGAR and SAR","volume":"307","author":"Reeder","year":"2023","journal-title":"Radiology"},{"issue":"1","key":"2025013017461258300_bib78","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/asheducation-2014.1.210","article-title":"Guidelines for quantifying iron overload","volume":"2014","author":"Wood","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2025013017461258300_bib79","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/jmri.21666","article-title":"Spleen R2 and R2\u2217 in iron-overloaded patients with sickle cell disease and thalassemia major","volume":"29","author":"Brewer","year":"2009","journal-title":"J\u00a0Magn Reson Imag"},{"issue":"22","key":"2025013017461258300_bib80","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood.2023021839","article-title":"Splenic iron decreases without change in volume or liver parameters during luspatercept therapy","volume":"142","author":"Denton","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025013017461258300_bib81","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.bbamcr.2015.01.021","article-title":"Cellular iron uptake, trafficking and metabolism: key molecules and mechanisms and their roles in disease","volume":"1853","author":"Lane","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"2025013017461258300_bib82","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIR.0b013e31829b2be6","article-title":"Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association","volume":"128","author":"Pennell","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"2025013017461258300_bib83","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2141.1995.tb08351.x","article-title":"Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major","volume":"89","author":"Cazzola","year":"1995","journal-title":"Br J Haematol"},{"issue":"2","key":"2025013017461258300_bib84","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.hoc.2022.12.013","article-title":"Clinical challenges with iron chelation in beta thalassemia","volume":"37","author":"Kwiatkowski","year":"2023","journal-title":"Hematol Oncol Clin N Am"},{"issue":"7","key":"2025013017461258300_bib85","first-page":"2010","article-title":"Safety and efficacy of the new combination iron chelation regimens in patients with transfusion-dependent thalassemia and severe iron overload","volume":"11","author":"Origa","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"2025013017461258300_bib86","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4103\/ijp.IJP_333_19","article-title":"Effectiveness and tolerability of twice daily dosing of deferasirox in unresponsive and intolerant transfusion-dependent beta-thalassemia patients: a narrative review","volume":"52","author":"Babu","year":"2020","journal-title":"Indian J Pharmacol"},{"issue":"6","key":"2025013017461258300_bib87","first-page":"1082","article-title":"Chelation protocols for the elimination and prevention of iron overload in thalassaemia","volume":"23","author":"Kolnagou","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"6","key":"2025013017461258300_bib88","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.12825","article-title":"Current approach to iron chelation in children","volume":"165","author":"Aydinok","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"2025013017461258300_bib89","doi-asserted-by":"crossref","first-page":"e31035","DOI":"10.1002\/pbc.31035","article-title":"Iron chelation therapy for children with transfusion-dependent beta-thalassemia: how young is too young?","volume":"71","author":"Forni","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2025013017461258300_bib90","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2009-11-250308","article-title":"The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores","volume":"116","author":"Wood","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2025013017461258300_bib91","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/bjh.14776","article-title":"Serum ferritin in the diagnosis of cardiac and liver iron overload in thalassaemia patients real-world practice: a multicentre study","volume":"182","author":"Krittayaphong","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"2025013017461258300_bib92","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.13002","article-title":"Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia","volume":"167","author":"Dee","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"2025013017461258300_bib93","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/pds.3657","article-title":"Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events","volume":"23","author":"Huang","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2025013017461258300_bib94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2352-4642(18)30335-3","article-title":"Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies","volume":"3","author":"Bird","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"2025013017461258300_bib95","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1196\/annals.1345.015","article-title":"Objectives and mechanism of iron chelation therapy","volume":"1054","author":"Hershko","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"2025013017461258300_bib96","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2007-07-102335","article-title":"Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications","volume":"111","author":"Sohn","year":"2008","journal-title":"Blood"},{"issue":"19","key":"2025013017461258300_bib97","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2009-05-222729","article-title":"Deferasirox pharmacokinetics in patients with adequate versus inadequate response","volume":"114","author":"Chirnomas","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2025013017461258300_bib98","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/08971900211038301","article-title":"Efficacy and tolerability of twice-daily dosing schedule of deferasirox in transfusion-dependent paediatric beta-thalassaemia patients: a randomized controlled study","volume":"36","author":"Panachiyil","year":"2023","journal-title":"J\u00a0Pharm Pract"},{"issue":"2","key":"2025013017461258300_bib99","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bcmd.2013.03.004","article-title":"Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose","volume":"51","author":"Pongtanakul","year":"2013","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"2025013017461258300_bib100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/pbc.22826","article-title":"Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent beta-thalassemia","volume":"56","author":"Chang","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2025013017461258300_bib101","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3324\/haematol.2010.032862","article-title":"Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial","volume":"96","author":"Wood","year":"2011","journal-title":"Haematologica"},{"issue":"4","key":"2025013017461258300_bib102","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00019053-200725040-00005","article-title":"Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective","volume":"25","author":"Delea","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"2025013017461258300_bib103","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/cncr.34736","article-title":"Reply to \"hepatocellular carcinoma in thalassemia and other hemoglobinopathies\"","volume":"129","author":"Origa","year":"2023","journal-title":"Cancer"},{"key":"2025013017461258300_bib104","doi-asserted-by":"crossref","first-page":"100585","DOI":"10.1016\/j.blre.2019.06.002","article-title":"Thalassemia and malignancy: an emerging concern?","volume":"37","author":"Hodroj","year":"2019","journal-title":"Blood Rev"},{"issue":"11","key":"2025013017461258300_bib105","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/jech-2014-205075","article-title":"Thalassaemia and risk of cancer: a population-based cohort study","volume":"69","author":"Chung","year":"2015","journal-title":"J\u00a0Epidemiol Community Health"},{"issue":"1","key":"2025013017461258300_bib106","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2352-4642(18)30350-X","article-title":"Renal function abnormalities and deferasirox","volume":"3","author":"Kattamis","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"issue":"12","key":"2025013017461258300_bib107","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3390\/children8121104","article-title":"Kidney tubular damage secondary to deferasirox: systematic literature review","volume":"8","author":"Scoglio","year":"2021","journal-title":"Children"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/4\/359\/2351982\/blood_bld-2023-022502-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/4\/359\/2351982\/blood_bld-2023-022502-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T12:46:46Z","timestamp":1738241206000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/4\/359\/517878\/Management-of-iron-overload-lessons-from"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":107,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,1,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022502","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}